CXCR3 Expression Pattern on CD4+ T Cells and IP-10 Levels with Regard to the HIV-1 Reservoir in the Gut-Associated Lymphatic Tissue

(1) Background: The gut-associated lymphatic tissue (GALT) represents the largest lymphoid organ, and is considered to be the largest HIV reservoir. The exact size of the GALT reservoir remains unclear. Several markers, such as the chemokine receptor CXCR3 and its pro-inflammatory ligand IP-10, have been proposed to define the size of HIV reservoirs in the peripheral blood (PB). However, little is known about the role of CXCR3 and IP-10 within the GALT. (2) Methods: We compared the CXCR3 expression, IP-10 levels, and cell-associated HIV DNA of distinct memory CD4+ T cell subsets from the terminal ileum (TI), PB and rectum (RE) of 18 HIV+ patients with antiretroviral therapy (ART), 6 HIV+ treatment-naive patients and 16 healthy controls. (3) Results: While the relative distributions of CD4+ T cell subsets were similar in PB, TI and RE, HIV DNA and CXCR3 expression were markedly increased and IP-10 levels were decreased in TI when compared to PB. No significant correlation was found between the CXCR3 expression and memory CD4+ T cell subsets, IP-10 levels and the HIV DNA amounts measured in PB, TI or RE. (4) Conclusions: During a chronic HIV-1 infection, neither CXCR3 nor IP-10 are indicative of the size of the viral reservoir in the GALT (TI and RE).

[1]  D. Duffy,et al.  HIV DNA reservoir and elevated PD‐1 expression of CD4 T‐cell subsets particularly persist in the terminal ileum of HIV‐positive patients despite cART , 2021, HIV medicine.

[2]  S. Kent,et al.  CD73+ CD127high Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection , 2021, International journal of molecular sciences.

[3]  B. Berkhout,et al.  CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency , 2020, Cell reports.

[4]  J. Izopet,et al.  Increase of CXCR3+ T cells impairs Th17 cells recruitment in the small intestine mucosa through IFN-γ and IL-18 during treated HIV-1 infection. , 2019, The Journal of infectious diseases.

[5]  M. Sitbon,et al.  Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4+ T Cells and Offers an Opportunity to Tackle Infection. , 2019, Cell metabolism.

[6]  D. Hazuda,et al.  PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals , 2019, Nature Communications.

[7]  R. Apps,et al.  Evidence that CD32a does not mark the HIV-1 latent reservoir , 2018, Nature.

[8]  R. Siliciano,et al.  The role of CD32 during HIV-1 infection , 2018, Nature.

[9]  D. Hazuda,et al.  CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells , 2018, Science Translational Medicine.

[10]  W. Paxton,et al.  Blood CXCR3+ CD4 T Cells Are Enriched in Inducible Replication Competent HIV in Aviremic Antiretroviral Therapy-Treated Individuals , 2018, Front. Immunol..

[11]  C. Rouzioux,et al.  Impact of early cART on HIV blood and semen compartments at the time of primary infection , 2017, PloS one.

[12]  L. Hanna,et al.  Pathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 Infections , 2017, Front. Immunol..

[13]  J. Martinez-Picado,et al.  Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue , 2017, PloS one.

[14]  J. Mellors,et al.  Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation , 2017, PLoS pathogens.

[15]  Y. Lévy,et al.  CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses , 2017, Nature.

[16]  S. Lewin,et al.  Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus–Infected Individuals Receiving Suppressive Antiretroviral Therapy , 2017, The Journal of infectious diseases.

[17]  E. Bernasconi,et al.  Impairment of CCR6+ and CXCR3+ Th Cell Migration in HIV-1 Infection Is Rescued by Modulating Actin Polymerization , 2017, The Journal of Immunology.

[18]  J. Routy,et al.  HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy , 2016, AIDS.

[19]  J. Routy,et al.  New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy , 2016, Retrovirology.

[20]  F. Barré-Sinoussi,et al.  Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset , 2016, PLoS pathogens.

[21]  S. Lewin,et al.  Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy , 2016, AIDS.

[22]  A. Casrouge,et al.  Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studies , 2016, EMBO molecular medicine.

[23]  C. Tremblay,et al.  Identification of novel HIV-1 dependency factors in primary CCR4+CCR6+Th17 cells via a genome-wide transcriptional approach , 2015, Retrovirology.

[24]  William W. Agace,et al.  Regional specialization within the intestinal immune system , 2014, Nature Reviews Immunology.

[25]  F. Romerio,et al.  Longitudinal analysis of distribution and function of plasmacytoid dendritic cells in peripheral blood and gut mucosa of HIV infected patients. , 2014, The Journal of infectious diseases.

[26]  P. Lemey,et al.  The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time , 2013, Proceedings of the National Academy of Sciences.

[27]  D. Havlir,et al.  The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. , 2013, The Journal of infectious diseases.

[28]  Jeffrey N. Martin,et al.  Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers , 2013, AIDS.

[29]  J. García,et al.  Impact of highly active antiretroviral therapy initiation on CD4+ T-cell repopulation in duodenal and rectal mucosa , 2013, AIDS.

[30]  D. Asmuth,et al.  Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens , 2012, AIDS.

[31]  C. Chougnet,et al.  HIV-Induced T-Cell Activation/Exhaustion in Rectal Mucosa Is Controlled Only Partially by Antiretroviral Treatment , 2012, PloS one.

[32]  C. B. Hare,et al.  Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. , 2010, The Journal of infectious diseases.

[33]  G. Boucher,et al.  Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton , 2010, Proceedings of the National Academy of Sciences.

[34]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[35]  Mario Roederer,et al.  Emerging concepts in the immunopathogenesis of AIDS. , 2009, Annual review of medicine.

[36]  Z. Sun,et al.  The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut , 2009, Mucosal Immunology.

[37]  T. Chun,et al.  Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses , 2008, Mucosal Immunology.

[38]  D. Nickle,et al.  Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. , 2008, The Journal of infectious diseases.

[39]  S. Mehandru,et al.  Role of the gastrointestinal tract in establishing infection in primates and humans , 2008, Current opinion in HIV and AIDS.

[40]  M. Markowitz,et al.  Lack of Mucosal Immune Reconstitution during Prolonged Treatment of Acute and Early HIV-1 Infection , 2006, PLoS medicine.

[41]  D. Douek,et al.  HIV disease: fallout from a mucosal catastrophe? , 2006, Nature Immunology.

[42]  D. Price,et al.  CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[43]  Christine Hogan,et al.  Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[44]  J. Flamm,et al.  Severe CD4+ T-Cell Depletion in Gut Lymphoid Tissue during Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in Restoration following Highly Active Antiretroviral Therapy , 2003, Journal of Virology.

[45]  D. Markovitz,et al.  The C-X-C chemokine IP-10 stimulates HIV-1 replication. , 2003, Virology.

[46]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[47]  J S Cornes,et al.  Number, size, and distribution of Peyer's patches in the human small intestine , 1965, Gut.